论文部分内容阅读
现已确证恶性黑色素瘤病人具有细胞免疫和体液抗体两种免疫反应。作者用依赖补体的微量细胞毒性试验,测定了21例黑色素瘤病人血清的抗体活性,并探索了这种抗体与疾病的临床阶段,肿瘤大小,免疫系统反应性及对治疗反应的相互关系。收集复发的黑色素瘤病人切除肿瘤前的血清,56℃灭活,加入外源AB血型补体,使之与机械分离的新鲜肿瘤细胞反应;以正常人混合血清作对照。结果发现,10例局部性黑色素瘤病人的血清,有9例对自体瘤细胞显示毒性作用;而在11
It has been confirmed that patients with malignant melanoma have both immune responses to cellular immunity and humoral antibodies. Using a complement-dependent cytotoxicity assay, the authors determined the serum antibody activity of 21 melanoma patients and explored the clinical stage, tumor size, immune system responsiveness, and response to treatment response of the antibody and disease. The serum of the patients with relapsed melanoma was removed before the tumor was excised, inactivated at 56° C., and the complement of exogenous AB blood type was added to react with mechanically separated fresh tumor cells; normal human mixed serum was used as a control. The results showed that 9 of the 10 patients with localized melanoma had serum toxicities to autologous tumor cells;